Allergic Reactions

Patients with sniffles because of allergic conditions have different living fungi within their noses compared with healthy people, according to a study conducted in Portugal and published in Frontiers in Microbiology.

Although this year brought many advances in the treatment of food allergy, the FDA’s approval of omalizumab dominated our most popular coverage.

In early August, the FDA approved neffy epinephrine nasal spray to treat emergent type 1 allergic reactions in patients who weigh at least 66 pounds.

This year brought breakthroughs and important advances in asthma and allergy. Healio’s most popular stories in 2024 covered the long-anticipated approval of neffy epinephrine nasal spray and an update to anaphylaxis practice parameters.

The holiday season is a time for celebration, but it is also a challenging time to manage allergies. From scented candles and seasonal plants to holiday foods and winter cocktails, navigating this festive landscape can be difficult.

Anaphylaxis protocols in emergency medical services have outdated recommendations and guidelines, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ARS Pharmaceuticals announced its submission of a supplemental new drug application to the FDA for neffy 1 mg for the treatment of type 1 allergic reactions in children who weigh between 33 lb and 66 lb.

Healio has compiled August’s most-read news in asthma and allergy.

The European Commission has approved EURneffy for the emergency treatment of allergic reactions, according to a press release by ARS Pharmaceuticals, producer of the drug.

The FDA approved ARS Pharmaceuticals’ neffy epinephrine nasal spray for emergency allergic reactions in children and adults weighing at least 66 pounds.